Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20077466 | 0.86 | GRM5 (0.41) | GRM5SMN1; SMN2 | |
| SCHEMBL29561492 | 0.86 | GRM5 (0.41) | GRM5SMN1; SMN2 | |
| SCHEMBL10314849 | 0.85 | MAOB (0.47) | GRM5PDCD1CD274 | |
| SCHEMBL4275594 | 0.82 | GRM5 (0.61) | GRM5KDM4EALDH1A1L3MBTL1TSHR | |
| SCHEMBL16151972 | 0.81 | GRM5 (0.59) | GRM5HPGDMAPK1KDM4EALDH1A1 | |
| SCHEMBL10314859 | 0.80 | MAOB (0.56) | GRM5 | |
| SCHEMBL10314867 | 0.79 | BRD4 (0.45) | GRM5KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL10314864 | 0.78 | MAOB (0.61) | GRM5 | |
| SCHEMBL4426496 | 0.76 | GRM5 (0.44) | GRM5MAPTRAB9ASMN1; SMN2TSHR | |
| SCHEMBL10314854 | 0.74 | GRM5 (0.47) | GRM5HPGDMAPK1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853237-B2 | Naphthyridinone analogs as mGluR5 positive allosteric modulators | VANDERBILT UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| US-20120172391-A1 | NAPHTHYRIDINONE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172391-A1 | NAPHTHYRIDINONE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | GRM5, GRIK5, GRM1 | GRM5 1/4885HPGD 1729/4885MAPK1 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.